|
[1]TSOCHATZIS EA, BOSCH J, BURROUGHS AK.Liver cirrhosis[J].Lancet, 2014, 383 (9930) :1749-1761.
|
|
[2]SHAYTO RH, ABOU MR, SHARARA AI.Use of rifaximin in gastrointestinal and liver diseases[J].World J Gastroenterol, 2016, 22 (29) :6638-6651.
|
|
[3]BAJAJ JS, WADE JB, SANYAL AJ.Spectrum of neurocognitive impairment in cirrhosis:Implications for the assessment of hepatic encephalopathy[J].Hepatology, 2009, 50 (6) :2014-2021.
|
|
[4]PRASAD S, DHIMAN RK, DUSEJA A, et al.Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy[J].Hepatology, 2007, 45 (3) :549-559.
|
|
[5]PATIDAR KR, THACKER LR, WADE JB, et al.Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization[J].Am J Gastroenterol, 2014, 109 (11) :1757-1763.
|
|
[6]STEPANOVA M, MISHRA A, VENKATESAN C, et al.In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009[J].Clin Gastroenterol Hepatol, 2012, 10 (9) :1034-1341.
|
|
[7]BLEIBEL W, AL-OSAIMI AM.Hepatic encephalopathy[J].Saudi J Gastroenterol, 2012, 18 (5) :301-309.
|
|
[8]KAJI K, TAKAYA H, SAIKAWA S, et al.Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity[J].World J Gastroenterol, 2017, 23 (47) :8355-8366.
|
|
[9]WU D, WU SM, LU J, et al.Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy:A Meta-analysis[J].Gastroenterol Res Pract, 2013, 2013 (2) :236963.
|
|
[10]SHARMA BC, SHARMA P, LUNIA MK, et al.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy[J].Gastroenterol, 2013, 108 (9) :1458-1463.
|
|
[11]BASS NM, MULLEN KD, SANYAL A, et al.Rifaximin treatment in hepatic encephalopathy[J].N Engl J Med, 2010, 362 (12) :1071-1081.
|
|
[12]LOGUERCIO C, FEDERICO A, de GIROLAMO V, et al.Cyclic treatment of chronic hepatic encephalopathy with rifaximin.Results of a double-blind clinical study[J].Minerva Gastroenterol Dietol, 2003, 49 (1) :53-62.
|
|
[13]ORR JG, CURRIE CJ, BERNI E, et al.The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-alpha[J].Liver Int, 2016, 36 (9) :1295-1303.
|
|
[14]MAHARSHI S, SHARMA BC, SRIVASTAVA S, et al.Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed[J].Gut, 2015, 64 (8) :1341-1342.
|
|
[15]WILLIAMS R, JAMES OF, WARNES TW, et al.Evaluation of the efficacy and safety of rifaximin in the treatment of HE:A doubleblind, randomized, dose-finding multi-centre study[J].Eur J Gastroenterol Hepatol, 2000, 12 (2) :203-208.
|
|
[16]LYON KC, LIKER E, MARTELLO JL, et al.Retrospective crosssectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy[J].J Gastroenterol Hepatol, 2017, 32 (9) :1548-1552.
|
|
[17]VLACHOGIANNAKOS J, VIAZIS N, VASIANOPOULOU P, et al.Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J].J Gastroenterol Hepatol, 2013, 28 (3) :450-455.
|
|
[18]DONG T, ARONSOHN A, GAUTHAM RK, et al.Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J].Dig Dis Sci, 2016, 61 (12) :3621-3626.
|
|
[19]ELFERT A, ABO AL, SOLIMAN S, et al.Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J].Eur J Gastroenterol Hepatol, 2016, 28 (12) :1450-1454.
|
|
[20]MOSTAFA T, BADRA G, ABDALLAH M.The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients[J].Turk J Gastroenterol, 2015, 26 (2) :163-169.
|
|
[21]HANOUNEH MA, HANOUNEH IA, HASHASH JG, et al.The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2012, 46 (8) :709-715.
|
|
[22]ASSEM M, ELSABAAWY M.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:A prospective randomized openlabel comparative multicenter study[J].Hepatol Int, 2016, 10 (2) :377-385.
|
|
[23]GOEL A, RAHIM U, NGUYEN LH, et al.Systematic review with meta-analysis:Rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J].Aliment Pharmacol Ther, 2017, 46 (11-12) :1029-1036.
|
|
[24]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.
|
|
[25]BETRAPLLY NS, GILLEVET PM, BAJAJ JS.Gut microbiome and liver disease[J].Transl Res, 2017, 179:49-59.
|
|
[26]PISTIKI A, GALANI I, PYLERIS E, et al.In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth[J].Int J of Antimicrob Agents, 2014, 43 (3) :236.
|
|
[27]GAO J, OWYANG C.Rifaximin, gut microbes and mucosal inflammation:Unraveling a complex relationship[J].Gut Microbes, 2014, 5 (4) :571-575.
|
|
[28]ODENA G, MIQUEL M, SERAFIN A, et al.Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats[J].World J Gastroenterol, 2012, 18 (17) :2084-2091.
|
|
[29]KALAMBOKIS GN, MOUZAKI A, RODI M, et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :815-818.
|
|
[30]KIMER N, PEDERSEN JS, BUSK TM, et al.Rifaximin has no effect on hemodynamics in decompensated cirrhosis:A randomized, double-blind, placebo-controlled trial[J].Hepatology, 2017, 65 (2) :592-603.
|
|
[31]KIMER N, PEDERSEN JS, BUSK TM, et al.Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis;A randomized trial[J].J Gastroenterol Hepatol, 2018, 33 (1) :307-314.
|
|
[32]TANG XJ, ZENG X, XIE WF.Research advances in rifaximin for treatment and prevention of hepatic encephalopathy[J].Chin J Dig, 2015, 35 (2) :138-141. (in Chinese) 唐夏姣, 曾欣, 谢渭芬.利福昔明治疗和预防肝性脑病的研究进展[J].中华消化杂志, 2015, 35 (2) :138-141.
|
|
[33]MULLEN KD, SANYAL AJ, BASS NM, et al.Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy[J].Clin Gastroenterol Hepatol, 2014, 12 (8) :1390-1397.
|
|
[34]ELTAWIL KM, LARYEA M, PELTEKIAN K, et al.Rifaximin vs conventional oral therapy for hepatic encephalopathy:A meta-analysis[J].World J Gastroenterol, 2012, 18 (8) :767-777.
|
|
[35]BAJAJ JS, BARRETT AC, BORTEY E, et al.Prolonged remission from hepatic encephalopathy with rifaximin, results of a placebo crossover analysis[J].Aliment Pharmacol Ther, 2015, 41 (1) :39-45.
|
|
[36]REIGADAS E, ALCALA L, GOMEZ J, et al.Breakthrough clostridium difficile infection in cirrhotic patients receiving rifaximin[J].Clin Infect Dis, 2017.[Epub ahead of print]
|
DownLoad: